86 results about "Vaccinia" patented technology

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The present invention relates to vaccines based on viral vectors for delivery of antigens against infectious diseases. In particular, the present invention relates to a recombinantly modified vaccinia virus Ankara (MVA) encoding EBV antigens that elicit infectious mononuclear hyperplasia (IM) and different cancer types. The invention also relates to medical application of the recombinant MVA in prevention of diseases caused by EBV (Epstein-Barr Virus).

A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.

The invention relates to the technical field of biomedical engineering. The invention provides an application of an oncolytic vaccinia virus carrying a stritin interference sequence in an anti-tumor drug, a stritin inhibitor recombinant vector, an application of the stritin inhibitor recombinant vector in preparation of the anti-tumor drug, and an anti-tumor drug composition taking a stritin inhibitor or the stritin inhibitor recombinant vector as an active component. According to the present invention, the inhibition on the Stritin can be used for preparing the anti-tumor virus drug, and particularly the recombinant vector is formed by recombining the Stritin inhibitor and the vaccinia virus, such that the advantages of the Stritin inhibitor and the vaccinia virus can be combined, the new target spot is provided for the tumor virus treatment, and the broad clinical application prospect is provided.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.

The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

This invention relates to the fields of biotechnology and targeted therapy, specifically to a recombinant construct, a recombinant oncolytic virus, its construction method, and its applications. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes for CD16 and CD19 into the genome of an oncolytic vaccinia virus. The antibodies secreted by this recombinant virus can not only bridge NK cells and CD19-positive B-cell lymphoma cells, increasing the contact between NK cells and tumor cells and their accumulation within tumor tissue, but also synergize with the tumor-lysing effect of the oncolytic virus, breaking down the stromal barrier, reshaping the tumor microenvironment, and enhancing therapeutic efficacy.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention, exhibits a higher anti-cancer effect and safety than conventional vaccinia virus alone administration. Therefore, the pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention can be advantageously used for treating cancer.

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

To provide a method for efficiently capping RNA in vitro.SOLUTION: In some embodiments, the capping reaction can be done at high temperature using Vaccinia capping enzyme or variants thereof. In other embodiments, the capping reaction may comprise capping enzymes from amoebic large viruses, such as Faust, Mimivirus, or Moumouvirus, or variants thereof. Compositions and kits for practicing the methods are also provided.SELECTED DRAWING: None

The invention belongs to the field of clinical technology, and provides preparation and clinical application of growth differentiation factor 11 (GDF11) mRNA for promoting wound healing, and the preparation method comprises the following steps: S1, carrying out N1 psi modification on GDF11 mRNA, and replacing uracil in an original sequence with N1 psi; s2, synthesizing the modified GDF11 mRNA (messenger Ribonucleic Acid); s3, purifying the synthesized GDF11 mRNA (messenger Ribonucleic Acid), so as to obtain mRNA with modified nucleoside; by optimizing the preparation method of growth differentiation factor 11 (GDF11) mRNA, the preparation method comprises the following steps: performing N1 psi modification, synthesizing by adopting a vaccinia enzyme m capping 7G capping system, adding a poly (A) tail, purifying, and wrapping in lipid nanoparticles (LNP) to form a stable delivery system, so that the stability and translation efficiency of mRNA are remarkably improved, and the stability and translation efficiency of the GDF11 are remarkably improved. And the defects existing in treatment by directly using the GDF11 protein in the prior art are overcome, an efficient and safe new strategy is provided for diabetes wound treatment, and remarkable beneficial effects are achieved.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The invention relates to a novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-RFP and VVL [delta] TK [delta] N1L [delta] A41L-IL-27 with deletion of A41L genes and an application of the novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27. The novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-RFP is a vaccinia virus Lister strain, a TK gene, an N1L gene and an A41L gene are deleted at a fixed point, and the vector has tumor targeting, can carry an exogenous therapeutic gene, and is used for treating various solid tumors. The vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27 can kill tumor cells and express interleukin 27 at the same time, and the vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27 and the oncolytic vaccinia virus have a stronger anti-tumor effect. The virus vectors VVL [delta] TK [delta] N1L [delta] A41L-RFP and VVL [delta] TK [delta] N1L [delta] A41L-IL-27 provided by the invention can be used as a potential novel gene therapy drug for treating pancreatic cancer, colon cancer, lung cancer and other tumors.

The invention belongs to the technical field of biological medicines, and provides a heat stress protein HSP70 inhibitor and application thereof in preparation of antitumor drugs. Experiments prove that the heat stress protein HSP70 inhibitor can enhance the replication capacity of oncolytic viruses in tumor cells and enhance the anti-tumor immune activation capacity at the same time; the invention further proves that the oncoVV-shHSP70 can effectively inhibit the expression of the HSP70 protein, so that the survival rate of various cancer cells can be obviously reduced, the effect is obviously superior to that of a control virus oncoVV only lacking the TK gene, and meanwhile, the oncoVV-shHSP70 can promote the infiltration of CD8 < + >-T cells in tumor tissues. The HSP70 inhibitor can be used for preparing an anti-tumor virus drug, particularly, the HSP70 inhibitor and the vaccinia virus are recombined into a recombinant vector, the advantages of the HSP70 inhibitor and the vaccinia virus can be combined, a new target spot is provided for virus treatment of tumors, and the HSP70 inhibitor has a wide clinical application prospect.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment. More specifically, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of hematopoietic system damage or pancytopenia induced by cancer therapy. Furthermore, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of leukopenia induced by cancer therapy. Furthermore, the extract derived from rabbit skin inflamed by vaccinia virus may be suitable for regeneration.

The present invention relates to hepatitis B immune regimens and compositions. The present invention provides a method of treating chronic hepatitis B infection (CHB) in a human comprising the steps of: a) administering to the human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector, the replication-deficient chimpanzee adenovirus (ChAd) vector comprises a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector, the modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

The present invention provides genetically modified vaccinia virus which may be employed as an oncolytic viral vector, wherein the genetically modified vaccinia virus comprises a nucleic acid molecule encoding a modified matrix protein from a vesicular stomatitis virus and wherein the genetically modified vaccinia virus is fusogenic.

To provide newly adapted and / or more potent viruses and / or virus vectors useful for treatment of human diseases.SOLUTION: Disclosed herein is a novel immune-modulating vaccinia virus strain (IOVA) and derivatives thereof with high replication efficiency for use in the medicine. The novel vaccinia virus strain IOVA and derivatives thereof, vectors and recombinants have an ability to replicate in a mammal cancer line and being lytic or, in the case of cancer cells, oncolytic, and elicit an increased capacity to destroy cell-cycle activated cells and / or tumor cells, compared with the gold standard Vaccinia virus WR.SELECTED DRAWING: None

There is provided a method of treating chronic hepatitis B infection (CHB) and / or chronic hepatitis D infection (CHD) in a human, comprising the steps of:a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO);b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); andd) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.